Table 3.

Liver function tests in the PP population during anti-TB drug treatment.

	FDC Group (n=49)	SF Group (n=49)	p-value
Baseline AST level (U/L)	31(28–56)	23(18–37)	0.6
Peak AST level (U/L)	67(45–102)	55(33–60)	0.86
1st week	35(23–43)	24(19–31)	0.83
2nd week	36(28–57)	27(24–37)	0.41
4th week	38(21–43)	30(25–49)	0.42
8th week	36(31–57)	30(25–58)	0.41
12th week	33(29–54)	29(25–37)	0.93
16th week	40(29–45)	25(23–36)	0.20
Baseline ALT level (U/L)	20(17–41)	18(14–30)	0.79
Peak ALT level (U/L)	63(46–97)	46(26–102)	0.41
1st week	16(11–35)	15(12–26)	0.65
2nd week	24(17–66)	19(16–37)	0.19
4th week	21(16–37)	26(21–44)	0.93
8th week	23(19–46)	28(19–62)	0.55
12th week	39(20–47)	33(21–58)	0.97
16th week	24(21–39)	23(16–27)	0.26
Baseline T-BIL level (mg/dl)	0.85(0.59–.093)	0.6(0.45–1.22)	0.22
Peak T-BIL level (mg/dl)	1.21(0.98–1.54)	0.93(0.73–1.29)	0.03
1st week	0.76(0.55–0.99)	0.61(0.43–0.7)	0.28
2nd week	0.64(0.42–0.82)	0.66(0.36–0.84)	0.11
4th week	0.87(0.66–1.10)	0.72(0.57–0.89)	0.04
8th week	1.06(0.70–1.43)	0.57(0.44–0.97)	0.03
12th week	0.89(0.54–1.15)	0.77(0.46–1.07)	0.21
16th week	0.95(0.76–1.21)	0.65(0.47–1.08)	0.15

The data are presented as the median(range). AST=aspartate aminotransferase; ALT=alanine aminotransferase; T-BIL=total bilirubin; FDC=fixed-dose combination; SF=separate formulation